{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:40:13Z","timestamp":1789594813528,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T00:00:00Z","timestamp":1453075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/aps.2015.105","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T11:42:06Z","timestamp":1453117326000},"page":"322-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia"],"prefix":"10.1038","volume":"37","author":[{"given":"Xue","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yan","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,18]]},"reference":[{"key":"BFaps2015105_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","volume":"15","author":"P Seeman","year":"1994","unstructured":"Seeman P, Van Tol HH . Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 264\u201370.","journal-title":"Trends Pharmacol Sci"},{"key":"BFaps2015105_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/RRS-200029981","volume":"24","author":"KA Neve","year":"2004","unstructured":"Neve KA, Seamans JK, Trantham-Davidson H . Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24: 165\u2013205.","journal-title":"J Recept Signal Transduct Res"},{"key":"BFaps2015105_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1124\/jpet.107.126706","volume":"324","author":"MJ Millan","year":"2008","unstructured":"Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 2008; 324: 587\u201399.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.schres.2005.07.025","volume":"79","author":"R Tandon","year":"2005","unstructured":"Tandon R, Fleischhacker WW . Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79: 145\u201355.","journal-title":"Schizophr Res"},{"key":"BFaps2015105_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25\u201343.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"BFaps2015105_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","volume":"31","author":"JC Schwartz","year":"2000","unstructured":"Schwartz JC, Diaz J, Pilon C, Sokoloff P . Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000; 31: 277\u201387.","journal-title":"Brain Res Brain Res Rev"},{"key":"BFaps2015105_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/cercor\/bhh202","volume":"15","author":"SB Glickstein","year":"2005","unstructured":"Glickstein SB, Desteno DA, Hof PR, Schmauss C . Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2005; 15: 1016\u201324.","journal-title":"Cereb Cortex"},{"key":"BFaps2015105_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/BF02346178","volume":"97","author":"S Shaikh","year":"1996","unstructured":"Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996; 97: 714\u20139.","journal-title":"Hum Genet"},{"key":"BFaps2015105_CR9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)39332-2","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1048\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","volume":"294","author":"C Reavill","year":"2000","unstructured":"Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000; 294: 1154\u201365.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(24)39333-4","volume":"293","author":"MJ Millan","year":"2000","unstructured":"Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M . S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1063\u201373.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/jpet.107.134536","volume":"324","author":"MJ Millan","year":"2008","unstructured":"Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, et al. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008; 324: 1212\u201326.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1369-1600.2011.00317.x","volume":"17","author":"R Song","year":"2012","unstructured":"Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, et al. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 2012; 17: 259\u201373.","journal-title":"Addict Biol"},{"key":"BFaps2015105_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbr.2007.07.033","volume":"186","author":"J Karasawa","year":"2008","unstructured":"Karasawa J, Hashimoto K, Chaki S . D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008; 186: 78\u201383.","journal-title":"Behav Brain Res"},{"key":"BFaps2015105_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.neuropharm.2005.01.007","volume":"48","author":"M Luttgen","year":"2005","unstructured":"Luttgen M, Elvander E, Madjid N, Ogren SO . Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat. Neuropharmacology 2005; 48: 830\u201352.","journal-title":"Neuropharmacology"},{"key":"BFaps2015105_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00210-003-0788-2","volume":"368","author":"A Newman-Tancredi","year":"2003","unstructured":"Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, et al. Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 188\u201399.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFaps2015105_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/379606a0","volume":"379","author":"B Giros","year":"1996","unstructured":"Giros B, Jaber M, Jones SR, Wightman RM, Caron MG . Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606\u201312.","journal-title":"Nature"},{"key":"BFaps2015105_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/PL00005263","volume":"358","author":"A Ekman","year":"1998","unstructured":"Ekman A, Nissbrandt H, Heilig M, Dijkstra D, Eriksson E . Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 342\u201350.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFaps2015105_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2009.10.068","volume":"627","author":"AV Yarkov","year":"2010","unstructured":"Yarkov AV, Der TC, Joyce JN . Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3\/D2 antagonists does not occur through the dopamine D3 receptor. Eur J Pharmacol 2010; 627: 167\u201372.","journal-title":"Eur J Pharmacol"},{"key":"BFaps2015105_CR20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0028-3908(99)00064-7","volume":"38","author":"D Boulay","year":"1999","unstructured":"Boulay D, Depoortere R, Perrault G, Borrelli E, Sanger DJ . Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2\/D3 receptor agonists. Neuropharmacology 1999; 38: 1389\u201396.","journal-title":"Neuropharmacology"},{"key":"BFaps2015105_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","volume":"27","author":"TH Svensson","year":"2003","unstructured":"Svensson TH . Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1145\u201358.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFaps2015105_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0028-3908(03)00145-X","volume":"45","author":"L Leriche","year":"2003","unstructured":"Leriche L, Schwartz JC, Sokoloff P . The dopamine D receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 2003; 45: 174\u201381.","journal-title":"Neuropharmacology"},{"key":"BFaps2015105_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","volume":"386","author":"P Sokoloff","year":"2013","unstructured":"Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R . Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 107\u201324.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFaps2015105_CR24","first-page":"255","volume":"95","author":"ED French","year":"1989","unstructured":"French ED, Levenson S, Ceci A . Characterization of the actions of phencyclidine on midbrain dopamine neurons. NIDA Res Monogr 1989; 95: 255\u201363.","journal-title":"NIDA Res Monogr"},{"key":"BFaps2015105_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/schbul\/sbr133","volume":"38","author":"A Adell","year":"2012","unstructured":"Adell A, Jimenez-Sanchez L, Lopez-Gil X, Romon T . Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr Bull 2012; 38: 9\u201314.","journal-title":"Schizophr Bull"},{"key":"BFaps2015105_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.euroneuro.2013.05.006","volume":"23","author":"S Nakajima","year":"2013","unstructured":"Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, et al. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur Neuropsychopharmacol 2013; 23: 799\u2013813.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFaps2015105_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s002130100799","volume":"156","author":"NR Swerdlow","year":"2001","unstructured":"Swerdlow NR, Geyer MA, Braff DL . Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001; 156: 194\u2013215.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFaps2015105_CR28","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/sj.npp.1300985","volume":"31","author":"M Zhang","year":"2006","unstructured":"Zhang M, Ballard ME, Kohlhaas KL, Browman KE, Jongen-Relo AL, Unger LV, et al. Effect of dopamine D3 antagonists on PPI in DBA\/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006; 31: 1382\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"BFaps2015105_CR29","unstructured":"Zhang M, Ballard ME, Drescher K, Gross G, Decker MW, LE R . Evaluation of D3 receptor involvement in psychosis: studies in preclinical animal models. 33th Annual Meeting 2003; Society of Neuroscience."},{"key":"BFaps2015105_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2007.04.021","volume":"182","author":"M Zhang","year":"2007","unstructured":"Zhang M, Ballard ME, Unger LV, Haupt A, Gross G, Decker MW, et al. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res 2007; 182: 1\u201311.","journal-title":"Behav Brain Res"},{"key":"BFaps2015105_CR31","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1523\/JNEUROSCI.19-11-04627.1999","volume":"19","author":"RJ Ralph","year":"1999","unstructured":"Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M, et al. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 1999; 19: 4627\u201333.","journal-title":"J Neurosci"},{"key":"BFaps2015105_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0893-133X(00)00150-0","volume":"23","author":"K Wedzony","year":"2000","unstructured":"Wedzony K, Mackowiak M, Zajaczkowski W, Fijal K, Chocyk A, Czyrak A . WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 2000; 23: 547\u201359.","journal-title":"Neuropsychopharmacology"},{"key":"BFaps2015105_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/jpet.109.162123","volume":"333","author":"A Gogos","year":"2010","unstructured":"Gogos A, Kwek P, Chavez C, van den Buuse M . Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther 2010; 333: 218\u201327.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0006-3223(90)90657-N","volume":"28","author":"ML Wadenberg","year":"1990","unstructured":"Wadenberg ML, Ericson E, Magnusson O, Ahlenius S . Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiatry 1990; 28: 297\u2013307.","journal-title":"Biol Psychiatry"},{"key":"BFaps2015105_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","volume":"25","author":"ML Wadenberg","year":"2001","unstructured":"Wadenberg ML, Soliman A, VanderSpek SC, Kapur S . Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001; 25: 633\u201341.","journal-title":"Neuropsychopharmacology"},{"key":"BFaps2015105_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","volume":"23","author":"ML Wadenberg","year":"1999","unstructured":"Wadenberg ML, Hicks PB . The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999; 23: 851\u201362.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFaps2015105_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF01244451","volume":"83","author":"ML Wadenberg","year":"1991","unstructured":"Wadenberg ML, Ahlenius S . Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 1991; 83: 43\u201353.","journal-title":"J Neural Transm Gen Sect"},{"key":"BFaps2015105_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3758\/PBR.16.4.729","volume":"16","author":"ME Young","year":"2009","unstructured":"Young ME, Sutherland S . The spatiotemporal distinctiveness of direct causation. Psychon Bull Rev 2009; 16: 729\u201335.","journal-title":"Psychon Bull Rev"},{"key":"BFaps2015105_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","volume":"184","author":"B Grayson","year":"2007","unstructured":"Grayson B, Idris NF, Neill JC . Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007; 184: 31\u20138.","journal-title":"Behav Brain Res"},{"key":"BFaps2015105_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0893-133X(98)00116-X","volume":"21","author":"M Ahlander","year":"1999","unstructured":"Ahlander M, Misane I, Schott PA, Ogren SO . A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 1999; 21: 414\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"BFaps2015105_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","volume":"179","author":"J Laszy","year":"2005","unstructured":"Laszy J, Laszlovszky I, Gyertyan I . Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 2005; 179: 567\u201375.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFaps2015105_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","volume":"226","author":"R Zimnisky","year":"2013","unstructured":"Zimnisky R, Chang G, Gyertyan I, Kiss B, Adham N, Schmauss C . Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2013; 226: 91\u2013100.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFaps2015105_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.phrs.2010.02.003","volume":"61","author":"V Micale","year":"2010","unstructured":"Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Di Marzo V, et al. Enhanced cognitive performance of dopamine D3 receptor \"knock-out\" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid\/endovanilloid systems. Pharmacol Res 2010; 61: 531\u20136.","journal-title":"Pharmacol Res"},{"key":"BFaps2015105_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/npp.2011.254","volume":"37","author":"DJ Watson","year":"2012","unstructured":"Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC . Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 2012; 37: 770\u201386.","journal-title":"Neuropsychopharmacology"},{"key":"BFaps2015105_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.euroneuro.2008.07.012","volume":"19","author":"F Loiseau","year":"2009","unstructured":"Loiseau F, Millan MJ . Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists. Eur Neuropsychopharmacol 2009; 19: 23\u201333.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFaps2015105_CR46","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","volume":"100","author":"MJ Millan","year":"2007","unstructured":"Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, et al. Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007; 100: 1047\u201361.","journal-title":"J Neurochem"},{"key":"BFaps2015105_CR47","doi-asserted-by":"publisher","first-page":"377s","DOI":"10.1016\/S0924-9338(03)00077-4","volume":"17","author":"F Muller-Spahn","year":"2002","unstructured":"Muller-Spahn F . Current use of atypical antipsychotics. Eur Psychiatry 2002; 17: 377s\u201384s.","journal-title":"Eur Psychiatry"},{"key":"BFaps2015105_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B . Psycho-pharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps2015105_CR49","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/S0014-2999(97)00049-6","volume":"321","author":"MJ Millan","year":"1997","unstructured":"Millan MJ, Gressier H, Brocco M . The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 1997; 321: R7\u20139.","journal-title":"Eur J Pharmacol"},{"key":"BFaps2015105_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejphar.2007.06.035","volume":"572","author":"I Gyertyan","year":"2007","unstructured":"Gyertyan I, Saghy K . The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007; 572: 171\u20134.","journal-title":"Eur J Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2015105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:45:40Z","timestamp":1748753140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2015105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,18]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFaps2015105"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.105","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,18]]},"assertion":[{"value":"23 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}